TFF Pharmaceuticals, Inc. (TFFP)

NASDAQ: TFFP · IEX Real-Time Price · USD
0.700
-0.002 (-0.28%)
Mar 30, 2023, 10:54 AM EDT - Market open
-0.28%
Market Cap 25.34M
Revenue (ttm) 195,021
Net Income (ttm) -34.45M
Shares Out 36.19M
EPS (ttm) -1.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 16,832
Open 0.700
Previous Close 0.702
Day's Range 0.700 - 0.725
52-Week Range 0.620 - 7.700
Beta 1.21
Analysts Buy
Price Target 12.50 (+1,685.71%)
Earnings Date May 9, 2023

About TFFP

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 25, 2019
Employees 4
Stock Exchange NASDAQ
Ticker Symbol TFFP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for TFFP stock is "Buy." The 12-month stock price forecast is $12.5, which is an increase of 1,685.71% from the latest price.

Price Target
$12.5
(1,685.71% upside)
Analyst Consensus: Buy
Stock Forecasts

News

TFF Pharmaceuticals Reports Fourth Quarter 2022 and Full Year 2022 Financial Results

FORT WORTH, Texas, March 07, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing inn...

3 weeks ago - GlobeNewsWire

TFF Pharmaceuticals to Participate in the 35th Annual Roth Conference

FORT WORTH, Texas, March 06, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug pro...

3 weeks ago - GlobeNewsWire

3 Bargain Stocks Worth Buying at These 52-Week Lows

Who doesn't love a bargain? We look for deals in many places.

Other symbols: RGFSTKH
1 month ago - InvestorPlace

TFF Pharmaceuticals Appoints Harlan Weisman, M.D. as Permanent Chief Executive Officer

Dr. Harlan Weisman and recently appointed Chief Medical Officer Dr. Zamaneh Mikhak to Provide an Overview of the Corporate Strategy and 2023 Objectives

1 month ago - GlobeNewsWire

TFF Pharmaceuticals Announces the Appointment of Zamaneh Mikhak, M.D. as Chief Medical Officer

FORT WORTH, Texas, Jan. 09, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug prod...

2 months ago - GlobeNewsWire

TFF Pharmaceuticals Announces Leadership Transition

Glenn Mattes to step down as Chief Executive Officer and as a Member of the Board of Directors

4 months ago - GlobeNewsWire

TFF Pharmaceuticals Announces Closing of $12.3 Million Public Offering

Underwriters Exercise Their Option in Full Underwriters Exercise Their Option in Full

4 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of TFF Pharmaceuticals, Inc. - TFFP

New York, New York--(Newsfile Corp. - November 19, 2022) - Pomerantz LLP is investigating claims on behalf of investors of TFF Pharmaceuticals, Inc. ("TFF" or the "Company") (NASDAQ: TFFP). Such inves...

4 months ago - Newsfile Corp

TFF Pharmaceuticals Prices $10.675 Million Offering of Common Stock and Warrants

FORT WORTH, Texas, Nov. 18, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug prod...

4 months ago - GlobeNewsWire

TFF Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants

FORT WORTH, Texas, Nov. 17, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug prod...

4 months ago - GlobeNewsWire

TFF Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Clinical Proof-of-Concept Demonstrated in Compassionate Use in Two Case Studies with Voriconazole Inhalation Powder (TFF VORI)

4 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TFF Pharmaceuticals, Inc. - TFFP

NEW YORK , Nov. 14, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of TFF Pharmaceuticals, Inc. ("TFF" or the "Company") (NASDAQ: TFFP). Such investors are advised t...

4 months ago - PRNewsWire

TFF Pharmaceuticals to Hold Third Quarter 2022 Financial and Business Results Conference Call on November 14, 2022

Company conference call and webcast at 4:30 PM ET

5 months ago - GlobeNewsWire

TFF Pharmaceuticals Announces Collaboration with Aptar Pharma to Explore and Develop Intranasal Delivery of Dry Powder Vaccines and Dry Powder Therapeutics

Administration of dry powders will utilize Aptar Pharma's Unidose (UDS) Powder Nasal Spray System

5 months ago - GlobeNewsWire

TFF Pharmaceuticals Announces Second Patient Successfully Treated with Voriconazole Inhalation Powder Through Compassionate Use Program

Marks the Second Patient to Clinically Benefit from Administration of Voriconazole Inhalation Powder (TFF VORI) Using Thin Film Freezing-Based Technology

5 months ago - GlobeNewsWire

TFF Pharmaceuticals Announces Program Updates for Voriconazole Inhaled Powder and Tacrolimus Inhaled Powder Clinical Programs

FORT WORTH, Texas, Nov. 01, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug prod...

5 months ago - GlobeNewsWire

TFF Pharmaceuticals Announces Presentation of Data Featuring Applications of Thin Film Freezing Technology at AAPS PharmSci 360 Meeting

Two Presentations Featuring Thin Film Freezing Technology Selected for the Meeting's Special Poster Collections

6 months ago - GlobeNewsWire

TFF Pharmaceuticals to Participate in the Roth Inaugural Healthcare Opportunities Conference

FORT WORTH, Texas, Sept. 26, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug pro...

6 months ago - GlobeNewsWire

TFF Pharmaceuticals Announces Acceptance of Multiple Abstracts Featuring Applications of Thin Film Freezing Technology at the Upcoming AAPS PharmSci 360 Meeting

Two Abstracts Selected for Presentation as part of the Meeting's Special Poster Collections

6 months ago - GlobeNewsWire

TFF Pharmaceuticals Announces Presentation of Patient Data with Voriconazole Inhalation Powder (TFF VORI) at the 15th International Congress on Lung Transplantation

Dr. Bradley Gardiner from the Royal Alfred Hospital in Melbourne, Australia presented results from compassionate use of treating pulmonary fungal infections in a lung transplant patient

7 months ago - GlobeNewsWire

TFF Pharmaceuticals to Participate at The H.C. Wainwright 24th Annual Global Investment Conference

FORT WORTH, Texas, Sept. 06, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug pro...

7 months ago - GlobeNewsWire

TFF Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Phase 2 Inhaled Voriconazole Powder and Inhaled Tacrolimus Powder Programs Continue to Advance

8 months ago - GlobeNewsWire

TFF Pharmaceuticals to Hold Second Quarter 2022 Financial and Business Results Conference Call on August 11, 2022

Company conference call and webcast at 4:30 PM ET Company conference call and webcast at 4:30 PM ET

8 months ago - GlobeNewsWire

TFF Pharmaceuticals Expands R&D Operations with New Austin Facility

New Facility in Austin Will Enable Increased Capacity for Internal Pipeline Assets While Accommodating Growing Interest in Partnered Projects

9 months ago - GlobeNewsWire

TFF Pharmaceuticals to Participate at The JMP Securities Life Sciences Conference

FORT WORTH, Texas, June 09, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug prod...

10 months ago - GlobeNewsWire